Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized comparison of three oral contraceptive plus antiandrogen regimens for moderate to severe hirsutism
ACTRN12609000604202Phase 2Completed
- Sponsor
- Dr. Sefa Kelekci
- Start
- Aug 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of drospirenone, cyproterone, spironolactone and ethinyl estradiol in hirsutism (3 arms), sponsored by Dr. Sefa Kelekci. Primary endpoint: Decrease in hirsutism score. Started Aug 2006; status: completed.
02
Drugs
drospirenonecyproteronespironolactoneethinyl estradiol
03
Conditions
hirsutism
Beyond the preview
Go deeper on ACTRN12609000604202.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12609000604202.